2-氨甲基环己胺 | 40015-92-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 2-氨甲基环己胺
• 中文别名: 3-氨基甲基环己胺
• 英文名称: 2-aminomethylcyclohexylamine
• 英文别名: 2-(aminomethyl)cyclohexan-1-amine；trans 1-aminomethyl-2-aminocyclohexane；1-amino-2-aminomethylcyclohexane；1-aminomethyl-2-aminocyclohexane；cis-2-Aminomethyl-cyclohexylamine；cyclohexane-2-amine-1-methylamine
• CAS: 40015-92-7
• 化学式: C₇H₁₆N₂
• 分子量: 128.217
• InChiKey: ZUYYQGFCSKJGDO-UHFFFAOYSA-N

物化性质

• 沸点：
  200.3±8.0 °C(Predicted)
• 密度：
  0.923±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  52
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  rac-tartaric acid dibenzoate 、 2-氨甲基环己胺 生成 (1R,2R)-2-(aminomethyl)cyclohexan-1-amine;2,3-dibenzoyloxybutanedioic acid
  参考文献：
  名称：

  JOSITANI, JOSITOKU;NOMITI, YUEHJ

  摘要：

  DOI：
• 作为产物：
  描述：

  2-羟基环己烷甲腈 在 氨 、 氢气 、 sodium t-butanolate 作用下， 以 甲醇 为溶剂， 150.0 ℃ 、10.0 MPa 条件下， 生成 2-氨甲基环己胺
  参考文献：
  名称：

  2-氨甲基环己胺的合成方法

  摘要：

  本发明提供一种2‑氨甲基环己胺的合成方法，包括以下步骤：将环氧环己烷和氢氰酸在开环催化剂作用下反应，得到含有2‑羟基环己基甲腈的反应液；将上述含有2‑羟基环己基甲腈的反应液溶于溶剂中，加入氨、氨解催化剂和助剂，通入氢气，反应得到2‑氨甲基环己胺。上述2‑氨甲基环己胺的合成方法，采用价廉易得的环氧环己烷和资源严重过剩的氢氰酸为原料，经过两步即可合成附加值高的2‑氨甲基环己胺，反应方法简单、反应流程短、产品相对环氧环己烷的选择性可高达70%以上。

  公开号：

  CN106316865B

文献信息

• [EN] IMIDAZOLINE DERIVATIVES AS CXCR4 MODULATORS<br/>[FR] DÉRIVÉS D'IMIDAZOLINE UTILISÉS EN TANT QUE MODULATEURS DE CXCR4
  申请人：UNIV PARIS

  公开号：WO2020201096A1

  公开（公告）日：2020-10-08

  The present invention provides novel compounds of formula (I) and pharmaceutical compositions containing these compounds. The compounds of formula (I) can act as CXCR4 modulators that specifically target the CXCR4 minor pocket, and they have further been found to inhibit the production of inflammatory cytokines in immune cells, which renders these compounds highly advantageous for use in therapy, particularly in the treatment or prevention of an inflammatory disorder, an autoimmune disorder, an autoinflammatory disorder, or an interferonopathy, such as, e.g., lupus erythematosus, dermatomyositis or rheumatoid arthritis.

  本发明提供了化合物的新结构（I）及含有这些化合物的药物组合物。式（I）化合物可以作为CXCR4调节剂，特异性靶向CXCR4小口袋，并且进一步发现能够抑制免疫细胞中炎症细胞因子的产生，使得这些化合物在治疗中具有极大的优势，特别适用于治疗或预防炎症性疾病、自身免疫性疾病、自身炎症性疾病或干扰素病，例如红斑狼疮、皮肌炎或类风湿性关节炎。
• WATER SOLUBLE PLATINUM COMPLEXES FOR TUMOR TREATMENT AND PROCESS OF PREPARING SAME
  申请人：GUDUI BIOPHARMA TECHNOLOGY INC.

  公开号：US20150051387A1

  公开（公告）日：2015-02-19

  Disclosed are water-soluble platinum complexes for tumor treatment and preparation method, said platinum complexes being shown as formula (I); The present platinum complexes exhibiting superior cytotoxicity and efficacy compare to the clinical drug oxaliplatin, the design strategy of the present platinum complexes is to enhance the solubility and stability favor its clinical use.

  本文披露了一种用于肿瘤治疗的水溶性铂配合物及其制备方法，所述铂配合物表示为式（I）；本文的铂配合物在细胞毒性和疗效方面优于临床药物奥沙利铂，本文的铂配合物设计策略是增强其溶解性和稳定性，有利于其临床应用。
• (Ethylene)-(propylene) - triaminepentaacetic acid derivatives, process for their production, and their use for the production of pharmaceutical agents
  申请人：Schering AG

  公开号：US20030194371A1

  公开（公告）日：2003-10-16

  The invention relates to (ethylene)-(propylene)-triaminepentaacetic acid derivatives that are substituted on both the ethylene bridge and the propylene bridge, as well as conjugates of these compounds with biomolecules. The compounds and conjugates are suitable as agents for NMR diagnosis and radiodiagnosis as well as for radiotherapy.

  该发明涉及在乙烯桥和丙烯桥上取代的(乙烯)-(丙烯)-三胺五乙酸衍生物，以及这些化合物与生物分子的结合物。这些化合物和结合物适用于核磁共振诊断和放射诊断代理，以及放射治疗。
• FLUORINE-CONTAINING WATER SOLUBLE PLATINUM COMPLEXES FOR TUMOR TREATMENT AND PROCESS OF PREPARING SAME
  申请人：Wang Yiqiang

  公开号：US20150011740A1

  公开（公告）日：2015-01-08

  Disclosed are fluorine-containing highly water-soluble platinum complexes for tumor treatment and preparation method, said platinum complexes being shown as formula (I); The present fluorine-containing platinum complexes exhibiting superior cytotoxicity and efficacy compare to the clinical drug oxaliplatin, the design strategy of the present platinum complexes is to enhance the solubility and stability favor its clinical use.

  本发明公开了一种用于肿瘤治疗的含氟高水溶性铂配合物及其制备方法，该铂配合物的化学式为(I)。本发明的含氟铂配合物与临床药物奥沙利铂相比，表现出更优异的细胞毒性和疗效。本发明的设计策略是增强铂配合物的溶解度和稳定性，以便其在临床上使用。
• USE OF FLUORINE-CONTAINING WATER SOLUBLE PLATINUM COMPLEX IN PREPARING DRUGS FOR PREVENTION AND TREATMENT OF CANCERS
  申请人：GUDUI BIOPHARMA TECHNOLOGY INC.

  公开号：US20140349955A1

  公开（公告）日：2014-11-27

  Disclosed in the present invention is the use of a fluorine-containing in preparing drugs for the prevention and treatment of tumors, said platinum complex being shown as formula (I). Experiments have demonstrated that the present fluorine-containing water soluble platinum complex is highly water soluble and exhibiting superior cytotoxicity and efficacy compare to the clinical platinum drugs. Said complex alone or in combination with other chemotherapeutics is able to treat cancer in mammals, and in particular, humans, said cancers including lung cancer, colon cancer, head and neck cancer, prostate cancer, breast cancer, ovarian cancer, cervical cancer, leukemia, lymphoid cancer, skin cancer, pancreatic cancer, liver cancer, bladder cancer, esophageal cancer, gastric cancer, male genital cancer or bone cancer.

  本发明揭示了在制备预防和治疗肿瘤药物时使用含氟铂配合物，该铂配合物的化学式为（I）。实验证明，该含氟水溶性铂配合物具有高度的水溶性，与临床铂类药物相比，具有优越的细胞毒性和疗效。该配合物单独或与其他化疗药物联合使用，能够治疗哺乳动物，特别是人类的癌症，包括肺癌、结肠癌、头颈癌、前列腺癌、乳腺癌、卵巢癌、宫颈癌、白血病、淋巴癌、皮肤癌、胰腺癌、肝癌、膀胱癌、食管癌、胃癌、男性生殖器癌或骨癌。